Science and Research

OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation

Activation of the NLRP3 inflammasome induces maturation of IL-1beta and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active beta-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome. In vitro, nanomolar concentrations of OLT1177 reduced IL-1beta and IL-18 release following canonical and noncanonical NLRP3 inflammasome activation. The molecule showed no effect on the NLRC4 and AIM2 inflammasomes, suggesting specificity for NLRP3. In LPS-stimulated human blood-derived macrophages, OLT1177 decreased IL-1beta levels by 60% and IL-18 by 70% at concentrations 100-fold lower in vitro than plasma concentrations safely reached in humans. OLT1177 also reduced IL-1beta release and caspase-1 activity in freshly obtained human blood neutrophils. In monocytes isolated from patients with cryopyrin-associated periodic syndrome (CAPS), OLT1177 inhibited LPS-induced IL-1beta release by 84% and 36%. Immunoprecipitation and FRET analysis demonstrated that OLT1177 prevented NLRP3-ASC, as well as NLRP3-caspase-1 interaction, thus inhibiting NLRP3 inflammasome oligomerization. In a cell-free assay, OLT1177 reduced ATPase activity of recombinant NLRP3, suggesting direct targeting of NLRP3. Mechanistically, OLT1177 did not affect potassium efflux, gene expression, or synthesis of the IL-1beta precursor. Steady-state levels of phosphorylated NF-kappaB and IkB kinase were significantly lowered in spleen cells from OLT1177-treated mice. We observed reduced IL-1beta content in tissue homogenates, limited oxidative stress, and increased muscle oxidative metabolism in OLT1177-treated mice challenged with LPS. Healthy humans receiving 1,000 mg of OLT1177 daily for 8 d exhibited neither adverse effects nor biochemical or hematological changes.

  • Marchetti, C.
  • Swartzwelter, B.
  • Gamboni, F.
  • Neff, C. P.
  • Richter, K.
  • Azam, T.
  • Carta, S.
  • Tengesdal, I.
  • Nemkov, T.
  • D'Alessandro, A.
  • Henry, C.
  • Jones, G. S.
  • Goodrich, S. A.
  • St Laurent, J. P.
  • Jones, T. M.
  • Scribner, C. L.
  • Barrow, R. B.
  • Altman, R. D.
  • Skouras, D. B.
  • Gattorno, M.
  • Grau, V.
  • Janciauskiene, S.
  • Rubartelli, A.
  • Joosten, L. A. B.
  • Dinarello, C. A.

Keywords

  • Animals
  • Anti-Inflammatory Agents/chemistry/*pharmacology/therapeutic use
  • Caspase 1/metabolism
  • Cells, Cultured
  • Humans
  • Inflammasomes/*antagonists & inhibitors
  • Inflammation/chemically induced/immunology/*prevention & control
  • Interleukin-18/metabolism
  • Interleukin-1beta/metabolism
  • Lipopolysaccharides/toxicity
  • Macrophages/*drug effects/metabolism/pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NLR Family, Pyrin Domain-Containing 3 Protein/genetics/*metabolism
  • Nitriles/chemistry/*pharmacology/therapeutic use
  • *nlrp3
  • *caspase-1
  • *interleukin-1
  • Advisory Board, is co-Chief Scientific Officer, and receives compensation.
  • L.A.B.J. serves on Olatec's Scientific Advisory Board and receives compensation.
  • J.P.S.L. has equity in Olatec. D.B.S. serves as Chairman and Chief Executive
  • Officer of Olatec, R.B.B. serves as Chief Operating Officer of Olatec, and C.L.S.
  • and R.D.A. serve on Olatec's Scientific Advisory Board.
Publication details
DOI: 10.1073/pnas.1716095115
Journal: Proceedings of the National Academy of Sciences of the United States of America
Pages: E1530-E1539 
Number: 7
Work Type: Original
Location: UGMLC
Disease Area: ROR
Partner / Member: JLU
Access-Number: 29378952
See publication on PubMed

DZL Engagements

chevron-down